Myeloma Novel Drug Discovery Ver 1.2
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Observational study - sample collection only..
- Who it may be relevant to
- Registry conditions: Multiple Myeloma. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United Kingdom
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Investigation of the Activity of Novel Compounds for the Treatment of Myeloma and Mechanisms of Drug Resistance to Current Therapies
Overview
Myeloma is a bone marrow cancer with over 5000 patients diagnosed in the UK each year. Researchers are committed to improving understanding of myeloma and developing more effective treatments with fewer side effects in order to improve patient outcomes. In order to do this, researchers are collecting samples of blood and bone marrow to test the activity of potential new treatments in the laboratory and to understand what may be the cause of some treatments not working.
Interventions
- Other Observational study - sample collection only.
No intervention - blood and/or bone marrow sample collection only
Primary outcome measures
- Cell viability [Time frame: 12 months]
Eligibility criteria
Inclusion criteria
- Participants who have a diagnosis, or suspected diagnosis, of myeloma or related plasma cell disorder
- Participants who are undergoing a peripheral blood or bone marrow aspirate sampling for diagnostic, staging or follow-up purposes, before, whilst or after receiving anti-myeloma treatment
- Participants aged 18 years of age or above
- Participants willing to consent to an additional sample being taken at the time of their peripheral blood or bone marrow aspirate sampling
Exclusion criteria
- Participants unable to provide consent
- Participants with known active infectious diseases (e.g. HIV, Hepatitis B/C, COVID) that pose a risk to the use of the sample in the laboratory
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
United Kingdom · 1 center
- The Royal Marsden NHS Foundation Trust — Sutton
Identifiers
NCT: NCT05968417 · CCR5106